COMMUNIQUÉS West-GlobeNewswire

Transactions with shares and linked securities in Genmab A/S made by managerial employees and their closely associated persons
29/02/2024
Company Announcement COPENHAGEN, Denmark; February 29, 2024 – Genmab A/S (Nasdaq: GMAB) - In accordance with Article 19 of Regulation No. 596/2014 on Market Abuse and Implementing Regulation 2016/523, this document [...]
DAS Health Expands Reach to Senior Living Organizations with Recent Acquisition
29/02/2024
Tampa, Fla., Feb. 29, 2024 (GLOBE NEWSWIRE) -- DAS Health, a provider of healthcare IT and business solutions, proudly announces the acquisition of Agility Holdings, LLC d/b/a vcpi. This significant acquisition expands [...]
Synaptive Medical Welcomes Chris Marrus as New Chief Commercial Officer
29/02/2024
New position of Chief Commercial Officer established to drive sales and growth for Synaptive Chris Marrus brings extensive experience in innovative med tech to Synaptive having held senior leadership roles at INSIGHTEC [...]
Cue Biopharma’s Lead Clinical Asset, CUE-101, to be Featured at the 2024 Multi-disciplinary Head and Neck Cancers Symposium
29/02/2024
BOSTON, Feb. 29, 2024 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (Nasdaq: CUE), a clinical-stage biopharmaceutical company developing a novel class of therapeutic biologics to selectively modulate disease-specific T cells [...]
Virios Therapeutics Announces Fourth Quarter and Full Year 2023 Financial Results
29/02/2024
ATLANTA, Feb. 29, 2024 (GLOBE NEWSWIRE) -- Virios Therapeutics, Inc. (Nasdaq: VIRI) (the “Company”), a development-stage biotechnology company focused on advancing novel antiviral therapies to treat debilitating chronic [...]
Anaptys to Present at TD Cowen’s 44th Annual Health Care Conference and 2024 AAD Annual Meeting
29/02/2024
SAN DIEGO, Feb. 29, 2024 (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (Nasdaq: ANAB), a clinical-stage biotechnology company focused on delivering innovative immunology therapeutics, today announced that Daniel Faga, president [...]
Capsa Announces NexPak Automated Medication Packaging System
29/02/2024
COLUMBUS, Ohio, Feb. 29, 2024 (GLOBE NEWSWIRE) -- Capsa Healthcare , a leader in advanced healthcare workflow solutions, announces the new NexPak Automated Packaging System . NexPak gives pharmacies the most direct path [...]
AVITA Medical to Present at TD Cowen 44th Annual Health Care Conference
29/02/2024
VALENCIA, Calif., Feb. 29, 2024 (GLOBE NEWSWIRE) -- AVITA Medical, Inc. (NASDAQ: RCEL, ASX: AVH), a commercial-stage regenerative medicine company focused on first-in-class devices for wound care management and skin [...]
Tenax Therapeutics Announces Oral Presentation of Levosimendan for the Treatment of PH-HFpEF at THT 2024
29/02/2024
Dr. Sanjiv Shah, a renowned, global expert in the treatment of HFpEF and PH-HFpEF, will present data highlighting the use of levosimendan for the treatment of pulmonary hypertension due to heart failure with preserved [...]
AIM ImmunoTech Outlines Recent Progress Across Clinical Development Pipeline and Provides Business Update
29/02/2024
Company continues progress across Ampligen ® clinical development programs Growing body of promising data demonstrates Ampligen’s potential to address multiple high-value indications OCALA, Fla., Feb. 29, 2024 (GLOBE [...]
SciSparc Delivers Treatment for Autism Spectrum Disorder Clinical Trial Enabling Commencement of Dosing
29/02/2024
The SCI- 210 treatment is now available at clinical site for autism spectrum disorder clinical trial in pediatric patients, in accordance with enrollment initiat ion TEL AVIV, Israel, Feb. 29, 2024 (GLOBE NEWSWIRE) -- [...]
Yield10 Bioscience Reports that Proprietary Varieties of Winter Camelina Show Tolerance to Commonly Used Herbicides in First Field Tests
29/02/2024
-Herbicide tolerance is critical to planting the Camelina crop on large acreage for the biofuel and omega-3 oil markets WOBURN, Mass., Feb. 29, 2024 (GLOBE NEWSWIRE) -- Yield10 Bioscience, Inc. (Nasdaq:YTEN) (“Yield10” [...]
SpringWorks Therapeutics Announces European Medicines Agency Validation for Marketing Authorization Application of Nirogacestat for the Treatment of Adults with Desmoid Tumors
29/02/2024
Application based on Phase 3 DeFi trial in which nirogacestat significantly improved progression-free survival and objective response rate compared to placebo, with rapid and sustained improvements in symptom burden [...]
Independent Lab Confirms Immunogenicity and Protection with IMUNON’s IMNN-101 in a Live Virus Challenge Against SARS-CoV-2 Variant XBB.1.5
29/02/2024
Murine Study by the Wistar Institute Builds Upon Favorable Results Previously Reported by IMUNON With its Prototype PlaCCine Vaccine Modality LAWRENCEVILLE, N.J., Feb. 29, 2024 (GLOBE NEWSWIRE) -- IMUNON, Inc. (NASDAQ: [...]
CytoDyn Announces FDA Has Lifted Clinical Hold
29/02/2024
Webcast to Provide Company Update on March 5, 2024 VANCOUVER, Washington, Feb. 29, 2024 (GLOBE NEWSWIRE) -- CytoDyn Inc. (OTCQB: CYDY) ("CytoDyn" or the "Company"), a biotechnology company developing leronlimab, a CCR5 [...]
Intercept Announces FDA Acceptance of Supplemental New Drug Application for Ocaliva® (obeticholic acid) for the Treatment of PBC
29/02/2024
sNDA intended to satisfy post-marketing requirements to confirm a clinical benefit in patients with PBC Precedent-setting submission includes data from post-marketing studies COBALT and Study 401 as well as real-world [...]
TOMI Environmental Announces Additional iHP Custom Engineered System Installation Contracted for California
29/02/2024
FREDERICK, Md., Feb. 29, 2024 (GLOBE NEWSWIRE) -- TOMI Environmental Solutions, Inc.® (“TOMI”) (NASDAQ: TOMZ), a global company specializing in disinfection and decontamination solutions, today announced the signing of [...]
Autonomix Signs Key Clinical Agreements in Preparation to Begin March 2024 Human Clinical Trial
29/02/2024
Proof-of-concept (PoC) human clinical trial targeting multi-billion-dollar pancreatic cancer market through transvascular RF ablation Agreements represent final steps needed in order to commence patient enrollment, [...]
Kineta Announces Restructuring and Exploration of Strategic Alternatives
29/02/2024
SEATTLE, Feb. 29, 2024 (GLOBE NEWSWIRE) -- Kineta, Inc. (Nasdaq: KA), a clinical-stage biotechnology company focused on the development of novel immunotherapies in oncology that address cancer immune resistance, [...]

Pages